Viridian tumbles on positive data for key eye drug prospect

BioPharma Dive

The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.

pharminent March 31, 2026 (Last updated: March 31, 2026)

BioPharma Dive

The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.

Related Stories